Clinical effect observation of atorvastatin combined with dapagliflozin in the treatment of metabolic associated fatty liver disease
Gao Wa
Yang Qin
Abstract：Objective To analyze the clinical effect of atorvastatin combined with dapagliflozin in the treatment of metabolic associated fatty liver disease.Methods Totally 86 patients with metabolic associated fatty liver disease admitted to the Affiliated Hospital of Inner Mongolia Medical University from June 2021 to June 2023 were selected.They were divided into control group and observation group using a double blind random number table method,with 43 cases in each group.The control group was treated with atorvastatin;the observation group was treated with atorvastatin combined with dapagliflozin,and both groups were treated for 6 months.The liver function indicators,liver physical indicators,blood lipid indicators,and glucose lipid metabolism indicators before and after treatment of two groups were compared.Results After 6 months of treatment,the levels of alanine aminotransferase,aspartate aminotransferase,and alkaline phosphatase in the observation group were lower than those in the control group[(44±6)U/L vs(68±7)U/L,(37±4)U/L vs(45±4)U/L,(41±7)U/L vs(50±9)U/L](all P＜0.001).After 6 months of treatment,liver physical indicators including fatty liver index and liver hardness value in the observation group were lower than those in the control group,while the CT value of the liver/spleen was higher than that in the control group(all P＜0.05).After 6 months of treatment,the high-density lipoprotein cholesterol in the observation group was higher than that in the control group,while the levels of low-density lipoprotein cholesterol,triglycerides,and total cholesterol were lower than those in the control group(all P＜0.001).After 6 months of treatment,the glucose and lipid metabolism indicators homeostasis model assessment of insulin resistance and triacylglycerol glucose product index in the observation group were lower than those in the control group[(2.1±0.3)vs(2.7±0.5),(4.1±0.7)vs(4.6±0.6)](both P＜0.001).Conclusion The combination of atorvastatin and dapagliflozin in the treatment of metabolic associated fatty liver disease can improve patients'liver function,blood lipid indicators,and glucose lipid metabolism indicators.
Keywords：Metabolic associated fatty liver diseaseAtorvastatinDapagliflozin
Publication Date：2024-03-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 405-409 )